McLean Hospital - Harvard Medical School, Belmont, Massachusetts (D.S.J., S.J.K.), and Research Triangle Institute, Research Triangle Park, North Carolina (B.E.B.).
McLean Hospital - Harvard Medical School, Belmont, Massachusetts (D.S.J., S.J.K.), and Research Triangle Institute, Research Triangle Park, North Carolina (B.E.B.)
J Pharmacol Exp Ther. 2021 Aug;378(2):124-132. doi: 10.1124/jpet.121.000548. Epub 2021 May 13.
Monoamine releasers such as d-methamphetamine (d-MA) can reduce cocaine use in laboratory studies and have been forwarded for the management of cocaine use disorder (CUD). However, the proven abuse liability of d-MA has limited enthusiasm for clinical use. The levorotatory isomer of MA, l-MA, appears to have lesser stimulant effects, possibly due to its preferential norepinephrine-releasing properties compared with dopamine. The present study evaluated the abuse potential of l-MA by comparing its reinforcing effects with known stimulant drugs of abuse in nonhuman primates. Adult rhesus macaques ( = 4) responded for intravenous injections of cocaine, d-MA, methcathinone (MCAT), or l-MA under a fixed-ratio (FR) schedule of reinforcement; reinforcing effectiveness was evaluated using behavioral economic demand procedures. In a separate cohort ( = 9), daily activity and food-reinforced responding were assessed during 100 days of treatment with daily dosages of l-MA (2.3 mg/kg per day, i.v.) or d-MA (0.74 mg/kg per day, i.v.) previously shown to decrease cocaine self-administration. Results show that all drugs maintained self-administration, with peak injections reaching ∼100 inj per session for cocaine, MCAT, and d-MA and ∼50 inj per session for l-MA . In demand studies, self-administration of each drug gradually decreased as FR size increased. The exponential model of demand indicated that the reinforcing effectiveness of l-MA was significantly less than the other drugs studied. Chronic l-MA treatment did not appreciably alter daily activity and only transiently suppressed food-reinforced responding. These data, coupled with previous findings that l-MA effectively reduces stimulant self-administration, suggest that l-MA, or other norepinephrine-preferring releasers, may serve as agonist medication for CUD with lesser abuse liability than common psychostimulants. SIGNIFICANCE STATEMENT: Development of pharmacotherapies for cocaine use disorder remains a formidable challenge. Agonist-based therapies show promise, but enthusiasm is tempered by the abuse liability of previously proposed medications. This study evaluated the abuse liability and chronic treatment effects of methamphetamine's levorotatory isomer (l-MA). l-MA demonstrated lower abuse liability compared with commonly abused stimulants and produced few untoward effects. In the context of recent studies demonstrating that l-MA attenuates stimulant self-administration, these findings support l-MA's potential as a pharmacotherapy for stimulant addiction.
单胺释放剂,如 d- 苯丙胺(d-MA),可以减少可卡因在实验室研究中的使用,并已被提出用于治疗可卡因使用障碍(CUD)。然而,d-MA 被证明的滥用倾向限制了其在临床应用中的热情。MA 的左旋异构体,l-MA,似乎具有较小的兴奋剂作用,这可能是由于与多巴胺相比,它优先释放去甲肾上腺素。本研究通过比较其强化作用与非人类灵长类动物中已知的滥用兴奋剂,评估了 l-MA 的滥用潜力。成年恒河猴(=4)在固定比率(FR)强化程序下,对可卡因、d-MA、甲卡西酮(MCAT)或 l-MA 的静脉内注射进行了反应;通过行为经济学需求程序评估强化效果。在一个单独的队列中(=9),在每天接受 2.3mg/kg 静脉内 l-MA(=9)或 0.74mg/kg 静脉内 d-MA(=9)治疗的 100 天期间,评估了日常活动和食物强化反应,先前的研究表明,这些剂量可减少可卡因的自我给药。结果表明,所有药物都能维持自我给药,可卡因、MCAT 和 d-MA 的峰值注射量约为每轮 100 次,l-MA 的峰值注射量约为每轮 50 次。在需求研究中,随着 FR 大小的增加,每种药物的自我给药逐渐减少。需求的指数模型表明,l-MA 的强化效果明显低于研究中的其他药物。慢性 l-MA 治疗不会明显改变日常活动,仅短暂抑制食物强化反应。这些数据,加上先前的研究结果表明,l-MA 有效减少兴奋剂自我给药,表明 l-MA 或其他去甲肾上腺素优先释放剂,可能作为可卡因使用障碍的激动剂药物,具有比常见精神兴奋剂更低的滥用倾向。意义:开发可卡因使用障碍的药物治疗仍然是一个艰巨的挑战。基于激动剂的治疗方法显示出希望,但由于先前提出的药物的滥用倾向,热情受到了抑制。本研究评估了苯丙胺左旋异构体(l-MA)的滥用倾向和慢性治疗效果。与常用的兴奋剂相比,l-MA 的滥用倾向较低,且产生的不良影响较少。在最近的研究表明 l-MA 减弱兴奋剂自我给药的背景下,这些发现支持 l-MA 作为治疗兴奋剂成瘾的药物治疗的潜力。